Trimetazidine 35mg Modified-Release (MR) Tablet is a metabolic agent specifically indicated for the long-term treatment of angina pectoris. Unlike traditional heart medications that focus on blood flow or heart rate, Trimetazidine works at the cellular level. It helps the heart muscle maintain its energy metabolism even when oxygen supply is low, protecting the heart from the effects of ischemia (reduced blood flow).
By optimizing the way the heart uses energy, this medication helps reduce the frequency and severity of angina attacks, improves exercise tolerance, and enhances the overall quality of life for patients with chronic stable angina. It is typically used as an add-on therapy when other primary treatments are not sufficient.
Key Benefits & Features:
-
Cellular Heart Protection: Shields heart cells from damage during periods of low oxygen or reduced blood flow.
-
Reduces Angina Frequency: Helps decrease the number of chest pain episodes and the need for short-acting nitrates.
-
Improved Exercise Tolerance: Allows patients to stay active for longer periods without experiencing chest discomfort.
-
Modified-Release Formula: Designed for consistent, 24-hour protection with twice-daily dosing.
-
Metabolic Support: Enhances glucose oxidation in the heart, providing a more efficient energy source for the cardiac muscle.
Usage Instructions:
-
Dosage: Usually one (1) tablet (35mg) taken twice daily—once in the morning and once in the evening—or as directed by your cardiologist.
-
Administration: Swallow the tablet whole with water during meals. Do not crush or chew the tablet, as this will destroy the modified-release properties.
-
Important Note: This medication is for long-term maintenance and is not intended for the treatment of acute angina attacks.





